{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:29:56Z","timestamp":1775060996407,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106278","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:57:19Z","timestamp":1775055439000},"source":"Crossref","is-referenced-by-count":0,"title":["Neuro-Oncology Biotech Industry Progress Report 2025"],"prefix":"10.7759","author":[{"given":"Zoey A","family":"Croft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griffin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Keister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maille","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoaib","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Latzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamika","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafell","family":"Serulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David  J","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Boockvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies","volume":"24","author":"Pouyan A","year":"2025","unstructured":"Pouyan A, Ghorbanlo M, Eslami M, et al.. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025, 24:58. 10.1186\/s12943-025-02267-0","journal-title":"Mol Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3805","article-title":"Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma","volume":"27","author":"Andrews DW","year":"2021","unstructured":"Andrews DW, Judy KD, Scott CB, et al.. Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma. Clin Cancer Res. 2021, 27:1912-22. 10.1158\/1078-0432.CCR-20-3805","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0702","article-title":"Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients","volume":"20","author":"Lee IY","year":"2024","unstructured":"Lee IY, Hanft S, Schulder M, et al.. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients. Future Oncol. 2024, 20:579-91. 10.2217\/fon-2023-0702","journal-title":"Future Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi BD","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, et al.. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024, 390:1290-8. 10.1056\/NEJMoa2314390","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2087-z","article-title":"Neuro-oncology biotech industry progress report","volume":"128","author":"Chakraborty S","year":"2016","unstructured":"Chakraborty S, Bodhinayake I, Chiluwal A, Langer DJ, Ruggieri R, Symons M, Boockvar JA. Neuro-oncology biotech industry progress report. J Neurooncol. 2016, 128:175-82. 10.1007\/s11060-016-2087-z","journal-title":"J Neurooncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2020.1837984","article-title":"An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications","volume":"97","author":"Karanam NK","year":"2021","unstructured":"Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021, 97:1044-54. 10.1080\/09553002.2020.1837984","journal-title":"Int J Radiat Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.80","article-title":"NovoTTF-100A: a new treatment modality for recurrent glioblastoma","volume":"12","author":"Fonkem E","year":"2012","unstructured":"Fonkem E, Wong ET. NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Rev Neurother. 2012, 12:895-9. 10.1586\/ern.12.80","journal-title":"Expert Rev Neurother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.01.005","article-title":"Critical review of the addition of Tumor Treating Fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients","volume":"111","author":"Mehta M","year":"2017","unstructured":"Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of Tumor Treating Fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017, 111:60-5. 10.1016\/j.critrevonc.2017.01.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04348-w","article-title":"Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis","volume":"164","author":"Ballo MT","year":"2023","unstructured":"Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. J Neurooncol. 2023, 164:1-9. 10.1007\/s11060-023-04348-w","journal-title":"J Neurooncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03540-6","article-title":"Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice","volume":"148","author":"Shi W","year":"2020","unstructured":"Shi W, Blumenthal DT, Oberheim Bush NA, et al.. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. J Neurooncol. 2020, 148:489-500. 10.1007\/s11060-020-03540-6","journal-title":"J Neurooncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04682-7","article-title":"Global post\u2011marketing safety surveillance of tumor treating fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022","volume":"169","author":"Mrugala MM","year":"2024","unstructured":"Mrugala MM, Shi W, Iwomoto F, Lukas RV, Palmer JD, Suh JH, Glas M. Global post\u2011marketing safety surveillance of tumor treating fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022. J Neurooncol. 2024, 169:25-38. 10.1007\/s11060-024-04682-7","journal-title":"J Neurooncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn MJ","year":"2018","unstructured":"Taphoorn MJ, Dirven L, Kanner AA, et al.. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018, 4:495-504. 10.1001\/jamaoncol.2017.5082","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp R","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, et al.. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017, 318:2306-16. 10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms SA","year":"2019","unstructured":"Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019, 141:467-73. 10.1007\/s11060-018-03057-z","journal-title":"J Neurooncol"},{"key":"ref16","unstructured":"Oncomagnetic device a promising non-invasive weapon against deadly brain cancer cells. (2023). Accessed. October 9, 2025: https:\/\/www.houstonmethodist.org\/leading-medicine-blog\/articles\/2023\/mar\/oncomagnetic-device-a-promising-non-invasive...."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46758-w","article-title":"Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells","volume":"13","author":"Hambarde S","year":"2023","unstructured":"Hambarde S, Manalo JM, Baskin DS, Sharpe MA, Helekar SA. Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells. Sci Rep. 2023, 13:19264. 10.1038\/s41598-023-46758-w","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708017","article-title":"Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device","volume":"11","author":"Baskin DS","year":"2021","unstructured":"Baskin DS, Sharpe MA, Nguyen L, Helekar SA. Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device. Front Oncol. 2021, 11:708017. 10.3389\/fonc.2021.708017","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2019.00081","article-title":"Photodynamic therapy for the treatment of glioblastoma","volume":"6","author":"Cramer SW","year":"2019","unstructured":"Cramer SW, Chen CC. Photodynamic therapy for the treatment of glioblastoma. Front Surg. 2019, 6:81. 10.3389\/fsurg.2019.00081","journal-title":"Front Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003247","article-title":"Clinical benefits of photodynamic therapy using talaporfin sodium in patients with isocitrate dehydrogenase -wildtype diagnosed glioblastoma: a retrospective study of 100 cases","volume":"96","author":"Fujimoto Y","year":"2025","unstructured":"Fujimoto Y, Fujita Y, Tanaka K, et al.. Clinical benefits of photodynamic therapy using talaporfin sodium in patients with isocitrate dehydrogenase -wildtype diagnosed glioblastoma: a retrospective study of 100 cases. Neurosurgery. 2025, 96:1374-85. 10.1227\/neu.0000000000003247","journal-title":"Neurosurgery"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115696","article-title":"Sonodynamic therapy: transforming sound into light for hard-to-treat tumours","volume":"226","author":"Cressey P","year":"2025","unstructured":"Cressey P, Abd Shukor SB, Thanou M. Sonodynamic therapy: transforming sound into light for hard-to-treat tumours. Adv Drug Deliv Rev. 2025, 226:115696. 10.1016\/j.addr.2025.115696","journal-title":"Adv Drug Deliv Rev"},{"key":"ref22","unstructured":"Alpheus Medical announces positive Phase 1\/2 trial results for the treatment of recurrent high-grade gliomas. (2024). Accessed. October 9, 2025: https:\/\/alpheusmedical.com\/news\/alpheus-medical-announces-positive-phase-1-2-trial-results-for-the-treatment-of-recur...."},{"key":"ref23","unstructured":"SonALAsense presents preliminary data from clinical study in patients with deadly pediatric brain tumor. (2023). Accessed. October 9, 2025: https:\/\/www.sonalasense.com\/news\/sonalasense-presents-preliminary-data-from-clinical-study-in-patients-with-deadly-pe...."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1052306","article-title":"Radioembolization of yttrium-90 microspheres for hepatic malignancy","volume":"25","author":"Murthy R","year":"2008","unstructured":"Murthy R, Kamat P, Nu\u00f1ez R, Salem R. Radioembolization of yttrium-90 microspheres for hepatic malignancy. Semin Intervent Radiol. 2008, 25:48-57. 10.1055\/s-2008-1052306","journal-title":"Semin Intervent Radiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-00679-1","article-title":"Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model","volume":"10","author":"Pasciak AS","year":"2020","unstructured":"Pasciak AS, Manupipatpong S, Hui FK, et al.. Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model. EJNMMI Res. 2020, 10:96. 10.1186\/s13550-020-00679-1","journal-title":"EJNMMI Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22025","article-title":"MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas","volume":"44","author":"Carpentier A","year":"2012","unstructured":"Carpentier A, Chauvet D, Reina V, et al.. MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas. Lasers Surg Med. 2012, 44:361-8. 10.1002\/lsm.22025","journal-title":"Lasers Surg Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.10.022","article-title":"Contemporary applications of laser interstitial thermal therapy: a comprehensive systematic review","volume":"193","author":"Seaton MP","year":"2025","unstructured":"Seaton MP, Schmidt JC, Brown NJ, Sahyouni R, Khalessi AA, Ben-Haim S, Gonda DD. Contemporary applications of laser interstitial thermal therapy: a comprehensive systematic review. World Neurosurg. 2025, 193:356-72. 10.1016\/j.wneu.2024.10.022","journal-title":"World Neurosurg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-024-06238-0","article-title":"MR-guided laser interstitial thermal therapy in the treatment of brain tumors and epilepsy","volume":"166","author":"Nielsen SH","year":"2024","unstructured":"Nielsen SH, Rasmussen R. MR-guided laser interstitial thermal therapy in the treatment of brain tumors and epilepsy. Acta Neurochir (Wien). 2024, 166:344. 10.1007\/s00701-024-06238-0","journal-title":"Acta Neurochir (Wien)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac208","article-title":"Laser hyperthermia: past, present, and future","volume":"24","author":"Schupper AJ","year":"2022","unstructured":"Schupper AJ, Chanenchuk T, Racanelli A, Price G, Hadjipanayis CG. Laser hyperthermia: past, present, and future. Neuro Oncol. 2022, 24:S42-51. 10.1093\/neuonc\/noac208","journal-title":"Neuro Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.01.024","article-title":"Laser interstitial thermal therapy in gliomas","volume":"474","author":"Bozinov O","year":"2020","unstructured":"Bozinov O, Yang Y, Oertel MF, Neidert MC, Nakaji P. Laser interstitial thermal therapy in gliomas. Cancer Lett. 2020, 474:151-7. 10.1016\/j.canlet.2020.01.024","journal-title":"Cancer Lett"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-024-05970-x","article-title":"Functional magnetic resonance imaging (fMRI) as adjunct for planning laser interstitial thermal therapy (LITT) near eloquent structures","volume":"166","author":"Rifi Z","year":"2024","unstructured":"Rifi Z, Harary M, Walshaw PD, et al.. Functional magnetic resonance imaging (fMRI) as adjunct for planning laser interstitial thermal therapy (LITT) near eloquent structures. Acta Neurochir (Wien). 2024, 166:66. 10.1007\/s00701-024-05970-x","journal-title":"Acta Neurochir (Wien)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148613","article-title":"Hyperthermic laser ablation of recurrent glioblastoma leads to temporary disruption of the peritumoral blood brain barrier","volume":"11","author":"Leuthardt EC","year":"2016","unstructured":"Leuthardt EC, Duan C, Kim MJ, et al.. Hyperthermic laser ablation of recurrent glioblastoma leads to temporary disruption of the peritumoral blood brain barrier. PLoS One. 2016, 11:e0148613. 10.1371\/journal.pone.0148613","journal-title":"PLoS One"},{"key":"ref33","unstructured":"Our approach combining LTSL-Dox + LITT. (2025). Accessed. October 21, 2025: https:\/\/www.dnko.net\/our-scientific-approach."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2021.102484","article-title":"Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes","volume":"40","author":"Regenold M","year":"2022","unstructured":"Regenold M, Bannigan P, Evans JC, Waspe A, Temple MJ, Allen C. Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes. Nanomedicine. 2022, 40:102484. 10.1016\/j.nano.2021.102484","journal-title":"Nanomedicine"},{"key":"ref35","article-title":"A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model","volume":"60","author":"Needham D","year":"2000","unstructured":"Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60:1197-201.","journal-title":"Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2755-2","article-title":"The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells","volume":"137","author":"Zumbar CT","year":"2018","unstructured":"Zumbar CT, Usubalieva A, King PD, et al.. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neurooncol. 2018, 137:481-92. 10.1007\/s11060-018-2755-2","journal-title":"J Neurooncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: activity, chemoresistance and its overcoming","volume":"54","author":"Mosca L","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021, 54:100742. 10.1016\/j.drup.2020.100742","journal-title":"Drug Resist Updat"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.07.022","article-title":"Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer","volume":"65","author":"Fitzpatrick JM","year":"2014","unstructured":"Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014, 65:1198-204. 10.1016\/j.eururo.2013.07.022","journal-title":"Eur Urol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-013-9334-0","article-title":"The pharmacological bases of the antiangiogenic activity of paclitaxel","volume":"16","author":"Bocci G","year":"2013","unstructured":"Bocci G, Di Paolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis. 2013, 16:481-92. 10.1007\/s10456-013-9334-0","journal-title":"Angiogenesis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2305308","article-title":"Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and\/or paclitaxel","volume":"55","author":"Ahmed M","year":"2023","unstructured":"Ahmed M, Semreen AM, Giddey AD, et al.. Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and\/or paclitaxel. Ann Med. 2023, 55:2305308. 10.1080\/07853890.2024.2305308","journal-title":"Ann Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae009","article-title":"Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma","volume":"6","author":"Goldlust SA","year":"2024","unstructured":"Goldlust SA, Nabors LB, Hsu S, et al.. Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma. Neurooncol Adv. 2024, 6:vdae009. 10.1093\/noajnl\/vdae009","journal-title":"Neurooncol Adv"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0061","article-title":"TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells","volume":"11","author":"Fitzgerald DP","year":"2012","unstructured":"Fitzgerald DP, Emerson DL, Qian Y, et al.. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 2012, 11:1959-67. 10.1158\/1535-7163.MCT-12-0061","journal-title":"Mol Cancer Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos307","article-title":"Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies","volume":"15","author":"Verma N","year":"2013","unstructured":"Verma N, Cowperthwaite MC, Burnett MG, Markey MK. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013, 15:515-34. 10.1093\/neuonc\/nos307","journal-title":"Neuro Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae049","article-title":"Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET\/RANO group","volume":"26","author":"Galldiks N","year":"2024","unstructured":"Galldiks N, Kaufmann TJ, Vollmuth P, et al.. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET\/RANO group. Neuro Oncol. 2024, 26:1181-94. 10.1093\/neuonc\/noae049","journal-title":"Neuro Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3171\/2022.12.JNS222173","article-title":"Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know","volume":"139","author":"Young JS","year":"2023","unstructured":"Young JS, Al-Adli N, Scotford K, Cha S, Berger MS. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg. 2023, 139:748-59. 10.3171\/2022.12.JNS222173","journal-title":"J Neurosurg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.26306","article-title":"Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques","volume":"49","author":"van Dijken BR","year":"2019","unstructured":"van Dijken BR, van Laar PJ, Smits M, Dankbaar JW, Enting RH, van der Hoorn A. Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques. J Magn Reson Imaging. 2019, 49:11-22. 10.1002\/jmri.26306","journal-title":"J Magn Reson Imaging"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1066191","article-title":"Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma","volume":"12","author":"Amidon RF","year":"2022","unstructured":"Amidon RF, Santos-Pinheiro F, Straza M, et al.. Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. Front Oncol. 2022, 12:1066191. 10.3389\/fonc.2022.1066191","journal-title":"Front Oncol"},{"key":"ref48","unstructured":"FTB maps. Accessed. October 9, 2025: https:\/\/imagingbiometrics.com\/our-solutions\/ftb-maps\/.."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6211","article-title":"Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making","volume":"40","author":"Iv M","year":"2019","unstructured":"Iv M, Liu X, Lavezo J, et al.. Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making. AJNR Am J Neuroradiol. 2019, 40:1649-57. 10.3174\/ajnr.A6211","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/neuopn\/okab029","article-title":"Magnetic resonance imaging mapping of brain tumor burden: clinical implications for neurosurgical management: case report","volume":"2","author":"Connelly JM","year":"2021","unstructured":"Connelly JM, Prah MA, Santos-Pinheiro F, Mueller W, Cochran E, Schmainda KM. Magnetic resonance imaging mapping of brain tumor burden: clinical implications for neurosurgical management: case report. Neurosurg Open. 2021, 2:okab029. 10.1093\/neuopn\/okab029","journal-title":"Neurosurg Open"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111644","article-title":"Fractional tumor burden maps increase the confidence of reading brain MR perfusion","volume":"178","author":"Herings SD","year":"2024","unstructured":"Herings SD, van der Wijk MW, von Beckerath V, Fasen BA, Meijer FJ, van der Kolk AG, Henssen DJ. Fractional tumor burden maps increase the confidence of reading brain MR perfusion. Eur J Radiol. 2024, 178:111644. 10.1016\/j.ejrad.2024.111644","journal-title":"Eur J Radiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.764665","article-title":"Medical imaging biomarker discovery and integration towards AI-based personalized radiotherapy","volume":"11","author":"Pang Y","year":"2021","unstructured":"Pang Y, Wang H, Li H. Medical imaging biomarker discovery and integration towards AI-based personalized radiotherapy. Front Oncol. 2021, 11:764665. 10.3389\/fonc.2021.764665","journal-title":"Front Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab065","article-title":"Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay","volume":"3","author":"Shuford S","year":"2021","unstructured":"Shuford S, Lipinski L, Abad A, et al.. Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv. 2021, 3:vdab065. 10.1093\/noajnl\/vdab065","journal-title":"Neurooncol Adv"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68801-0","article-title":"Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma","volume":"14","author":"Ledford A","year":"2024","unstructured":"Ledford A, Rodriguez A, Lipinski L, et al.. Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma. Sci Rep. 2024, 14:19474. 10.1038\/s41598-024-68801-0","journal-title":"Sci Rep"},{"key":"ref55","unstructured":"3D-PREDICT platform. Accessed. October 9, 2025: https:\/\/kiyatec.com\/healthcare-professionals\/3d-predict-platform\/."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51898-z","article-title":"NEMA performance evaluation of CareMiBrain dedicated brain PET and comparison with the whole-body and dedicated brain PET systems","volume":"9","author":"Moliner L","year":"2019","unstructured":"Moliner L, Rodr\u00edguez-Alvarez MJ, Catret JV, Gonz\u00e1lez A, Ilisie V, Benlloch JM. NEMA performance evaluation of CareMiBrain dedicated brain PET and comparison with the whole-body and dedicated brain PET systems. Sci Rep. 2019, 9:15484. 10.1038\/s41598-019-51898-z","journal-title":"Sci Rep"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-023-01984-7","article-title":"Objective image quality comparison between brain-dedicated PET and PET\/CT scanners","volume":"47","author":"Gandia-Ferrero MT","year":"2023","unstructured":"Gandia-Ferrero MT, Torres-Espallardo I, Mart\u00ednez-Sanchis B, et al.. Objective image quality comparison between brain-dedicated PET and PET\/CT scanners. J Med Syst. 2023, 47:88. 10.1007\/s10916-023-01984-7","journal-title":"J Med Syst"},{"key":"ref58","unstructured":"CareMiBrain. Accessed. October 9, 2025: https:\/\/oncovision.com\/caremibrain\/."},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236127","article-title":"A network-based approach to glioma surgery: insights from functional neurosurgery","volume":"13","author":"Samuel N","year":"2021","unstructured":"Samuel N, Vetkas A, Pancholi A, et al.. A network-based approach to glioma surgery: insights from functional neurosurgery. Cancers (Basel). 2021, 13:10.3390\/cancers13236127","journal-title":"Cancers (Basel)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.665016","article-title":"Resting-state functional magnetic resonance imaging networks as a quantitative metric for impact of neurosurgical interventions","volume":"15","author":"Yang PH","year":"2021","unstructured":"Yang PH, Hacker CD, Patel B, Daniel AG, Leuthardt EC. Resting-state functional magnetic resonance imaging networks as a quantitative metric for impact of neurosurgical interventions. Front Neurosci. 2021, 15:665016. 10.3389\/fnins.2021.665016","journal-title":"Front Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466392-neuro-oncology-biotech-industry-progress-report-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:57:21Z","timestamp":1775055441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466392-neuro-oncology-biotech-industry-progress-report-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.106278","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}